![Page 1: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/1.jpg)
INTRODUCTION TO VHLCourtney Schroeder, MS, LCGCOncology Genetic CounselorIndiana University Health
![Page 2: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/2.jpg)
OBJECTIVES
• Become familiar with the history of VHL• Understand the genetics of VHL• Recognize features of VHL• Learn how VHL is diagnosed• Become familiar with current screening recommendations• Learn about the IU Health Hereditary Renal Disease Clinic
![Page 3: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/3.jpg)
WHAT IS VHL?
• von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that increases one’s risk for several types of tumors
• Features of the condition can occur in childhood, adolescence or adulthood
• Hemangioblastomas of the brain, spinal cord and retina are characteristic features
American Society of Retina Specialists (ASRS) Wikipedia- VHLWikipedia- VHL
![Page 4: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/4.jpg)
1 in 36,000 people
![Page 5: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/5.jpg)
HISTORY OF VHL
• Eugene von Hippel first described tumors of the eye in 1904
• Arvid Lindau described tumors of the brain and spine in 1927
![Page 6: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/6.jpg)
GENETICS OF VHL
• VHL gene
• Autosomal dominant pattern
• Inherited- 80%• De novo 20%
• Different subtypes of VHL depending on gene mutation
![Page 7: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/7.jpg)
NSGC 2014
![Page 8: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/8.jpg)
Credit: Genome Decoration Page/NCBI
![Page 9: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/9.jpg)
![Page 10: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/10.jpg)
VHL
PheochromocytomaLow risk High risk
TYPE 1Hemangioblastomas
Kidney Cancer
deletions, insertions, truncations and
missense mutations
Kidney Cancer
No riskLow riskHigh risk
TYPE 2A TYPE 2CTYPE 2BHemangioblastomasPheochromocytomas
Pancreatic tumors
missense mutations
HemangioblastomasKidney Cancer
PheochromocytomasPancreatic tumors
missense mutations
Pheochromocytomasonly
missense mutations
GENOTYPE- PHENOTYPE
![Page 11: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/11.jpg)
CLINICAL MANIFESTATIONSBrain hemangioblastomas- 44-72%
Spinal cord hemangioblastomas-13-50%
Pheochromocytoma-10-20%Kidney Cancer- 25-60%Kidney cystsKidney hemangioblastoma
Broad ligament cystadenomas-10%
Epididymal cystadenomas-25-60%
Liver hemangioblastomas- 7%
Pancreatic tumor or cysts- 35-70%
Lung hemangioblastomas
Endolymphatic sac tumors- 10-25%Retinal angiomas- 25-60%
![Page 12: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/12.jpg)
WHAT ARE FEATURES OF VHL?• Hemangioblastomas
• Retinal – 12-25 yrs• Brain- 18-35 years• Spinal cord- 24-35 years
• Pancreatic lesions- 24-35 years• Cysts• Pancreatic neuroendocrine tumors
• Endolymphatic sac tumors- 24-35 years
• Kidney lesions- 25-50 years• Cysts• Kidney cancer- typically clear cell
NIH and VHL Alliance
![Page 13: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/13.jpg)
WHAT ARE FEATURES OF VHL?
• Pheochromocytomas-12-25 years• Majority are benign
• Epididymal cystadenomas- 14-40 years• Benign but may cause pain• If bilateral, may cause infertility
• Broad ligament cystadenomas- 16-46 years• Benign but may cause pain
![Page 14: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/14.jpg)
WHEN TO REFER?
• Family history of VHL
• Individuals with any of the following:• Hemangioblastoma (retina, brain or spine)• Pheochromocytoma• Kidney cancer <45 years old• Multiple kidney and pancreatic cysts• Pancreatic neuroendocrine tumors • Endolymphatic sac tumors• Multiple papillary cystadenomas of the epididymis or broad ligament
![Page 15: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/15.jpg)
HOW IS VHL DIAGNOSED?
• Simplex case (no family history) includes the presence of 2 or more features:
• ≥2 hemangioblastomas (retina, brain or spine) or 1 hemangioblastoma and multiple kidney or pancreatic cysts
• kidney cancer• pheochromocytoma• endolymphatic sac tumors, cystadenomas of the epididymis or broad ligament
or PNET
• Individual with family history plus 1 or more features:• spinal, retinal or brain hemangioblastoma• pheochromocytoma• kidney cancer• multiple kidney and pancreatic cysts
![Page 16: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/16.jpg)
WHAT ARE SCREENING RECOMMENDATIONS?Age Screening Frequency
Beginning at age 1 year
- physical exam with evaluation for neurological symptoms, hearing loss and blood pressure
- eye evaluation with indirect ophthalmoscope
Annually
Annually
Beginning at age 5 years
- plasma or 24-hr urine for fractionated metanephrines
- hearing assessment
Annually
Every 2-3 years
Beginning at age 8 years
- abdominal ultrasound Annually
Beginning at age 16 years
- MRI of the brain, spine and abdomen Every 2 years
VHL Alliance
![Page 17: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/17.jpg)
HEREDITARY RENAL DISEASE CLINIC
Patient
Urologist
Genetics
OncologistResearch
Nurses
![Page 18: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/18.jpg)
HEREDITARY CANCER SYNDROMES
Hereditary Leiomyomatosis
Renal Cell Carcinoma
von Hippel-Lindau
Birt-Hogg-Dubé
Tuberous Sclerosis Complex
62%
4%
15%
19%
![Page 19: INTRODUCTION TO VHL...Courtney Schroeder, MS, LCGC Oncology Genetic Counselor. Indiana University Health. OBJECTIVES • Become familiar with the history of VHL • Understand the](https://reader034.vdocuments.us/reader034/viewer/2022042803/5f4455b5220b8a540804763c/html5/thumbnails/19.jpg)